Kyle Holen is the Vice President and Therapeutic Area Head, General Medicine & Infectious Disease Abbvie. He is a trained as a medical oncologist at Columbia University and Memorial Sloan-Kettering Cancer Center, Kyle began his career treating patients with GI tumors at the University of Wisconsin. There, his research interests included early phase trials and novel therapies for GI and neuroendocrine tumors. His educational responsibilities included leading the UW medical oncology fellowship program. He left academia to pursue drug development at AbbVie in 2009 and has since held a variety of roles in the clinical development organization. He is currently the Vice President and Therapeutic Area Head of General Medicine and Infectious Diseases, responsible for the clinical development of products across many different indications including anti-infectives, women’s health, endocrinology, gastrointestinal diseases, pulmonology, cardiology, urology and others.